PATIENTS STARTING ON ACTEMRA
De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis: 2-year data from TENDER, a Phase 3 clinical trial. Presented at the European League Against Rheumatism 2012 in Berlin, Germany; June 6-9, 2012. EULAR Poster #FRI0328.
De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis: 2-year data from TENDER, a Phase 3 clinical trial. Presented at the European League Against Rheumatism 2012 in Berlin, Germany; June 6-9, 2012. EULAR Poster #FRI0328.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
Brunner H, et al. Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis. Presented at the 2018 CARRA Annual Scientific Meeting in Denver, Colorado; April 12-15, 2018. Poster 007.
Brunner H, et al. Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis. Presented at the 2018 CARRA Annual Scientific Meeting in Denver, Colorado; April 12-15, 2018. Poster 007.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.